Acute Hemodynamic Response to beta-Blockers and Prediction of Long-term Outcome in Primary Prophylaxis of Variceal Bleeding
Por:
Villanueva, C, Aracil, C, Colomo, A, Hernandez-Gea, V, Lopez-Balaguer, JM, Alvarez-Urturi, C, Torras, X, Balanzo, J, Guarner, C
Publicada:
1 jul 2009
Resumen:
BACKGROUND & AIMS: Studies of variceal bleeding have shown that a hemodynamic response to treatment of portal hypertension is appropriate when the hepatic venous pressure gradient (HVPG) decreases below 12 mmHg or by >20% from baseline. However, in primary prophylaxis, many nonresponders do not bleed and 2 invasive procedures are needed to assess response. We investigated the long-term prognostic value of an acute response to beta-blockers and whether the target reduction in HVPG can be improved in primary prophylaxis. METHODS: An initial hemodynamic study was performed in patients with large varices and without previous bleeding. After baseline measurements were made, propranolol was administered intravenously and measurements were repeated 20 minutes later. Patients were given nadolol daily and a second hemodynamic study was performed. RESULTS: Of 105 patients, 15% had variceal bleeding. Using receiver operating characteristic curve analysis, a decrease of HVPG >= 10% was the best value to predict bleeding. In the initial study, 75 patients (71%) were responders (HVPG decreased to <= 12 mmHg or by >= 10%) and had a lower probability of first bleeding than nonresponders (4% vs 46% at 24 months; P < .001). Acute responders also had a lower risk of developing ascites (P = .001). Chronic responders had a lower probability of bleeding than nonresponders (P < .001). There was a correlation between acute and chronic changes in HVPG (r = 0.62; P = .01). CONCLUSION: The acute hemodynamic response to beta-blockers can be used to predict the long-term risk of first bleeding. An HVPG reduction > 10% from baseline is the best target to define response in primary prophylaxis.
To view this article's video abstract, go to the AGA's YouTube Channel.
Filiaciones:
Villanueva, C:
Autonomous Univ Barcelona, Hosp Santa Creu & Sant Pau, Dept Gastroenterol, Gastrointestinal Bleeding Unit,Serv Patol Digest, Barcelona 08025, Spain
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain
Colomo, A:
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain
Torras, X:
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain
Balanzo, J:
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain
Guarner, C:
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain
|